Townsend Adam J. 4
4 · Apellis Pharmaceuticals, Inc. · Filed Dec 5, 2023
Insider Transaction Report
Form 4
Townsend Adam J.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-12-01$60.50/sh−67,557$4,087,327→ 118,850 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-01−110,000→ 172,500 totalExercise: $15.09Exp: 2028-11-15→ Common Stock (110,000 underlying) - Sale
Common Stock
2023-12-01$61.31/sh−42,443$2,601,977→ 76,407 total - Exercise/Conversion
Common Stock
2023-12-01$15.09/sh+110,000$1,659,900→ 186,407 total
Footnotes (6)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $60 - $60.995. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $61 - $61.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This includes 412 shares from 4/30/2023 ESPP purchase.
- [F5]This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.
- [F6]This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.